Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer and Merck KGaA win over NICE on Bavencio coverage

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Apr 07, 2022 12:40pm

219 Views

Post# 34584751

Pfizer and Merck KGaA win over NICE on Bavencio coverage

April 07, 2022 - Bavencio now has routine NHS coverage in the UK as a front-line maintenance treatment of bladder cancer that hasn’t progressed after platinum-based chemotherapy.

https://www.fiercepharma.com/pharma/appeal-pfizer-and-merck-kgaa-convince-nice-back-bavencio-bladder-cancer

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1